Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

Who will be the biggest pharma players in orphan drugs?
Pharmaforum
Sat, 09/7/19 - 06:25 pm
Tags:
orphan drugs, Roche, M&A, AbbVie, JNJ
Skyrizi looks ready to soar after strong launch
Biopharma Dive
Wed, 09/4/19 - 11:23 pm
Tags:
AbbVie, Skyrizi, psoriasis
Rova-T: the story of AbbVie’s multi-billion dollar failure
Pharmaforum
Wed, 09/4/19 - 10:12 am
Tags:
AbbVie, lung cancer, M&A, Stemcentrx, Rova-T
$5.8B for Nothing: AbbVie Shelves Stemcentryx Drug After Latest Flop
Xconomy
Thu, 08/29/19 - 10:33 am
Tags:
AbbVie, Stemcentryx, Rova-T
FDA issues safety warning for newer hepatitis C drugs following patient deaths
Biopharma Dive
Wed, 08/28/19 - 11:02 pm
Tags:
FDA, hepatitis C, FAERS, AbbVie, Mavyret, Merck, Zepatier, Gilead Sciences, Vosevi
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Endpoints
Wed, 08/28/19 - 12:38 pm
Tags:
Bristol-Myers Squibb, AbbVie, Empliciti, Celgene, Europe, relapsed or refractory multiple myeloma
AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira
Motley Fool
Tue, 08/20/19 - 10:39 am
Tags:
AbbVie, Rinvoq, Humira, immunology
AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
Fierce Pharma
Tue, 08/20/19 - 09:45 am
Tags:
JAK inhibitors, AbbVie, Rinvoq, FDA, Gilead Sciences
Price, safety will test blockbuster billing for AbbVie's new arthritis drug
Biopharma Dive
Sat, 08/17/19 - 12:14 am
Tags:
AbbVie, rheumatoid arthritis, drug pricing, Rinvoq
Rinvoq approval bolsters AbbVie's autoimmune portfolio
BioCentury
Fri, 08/16/19 - 11:54 pm
Tags:
AbbVie, FDA, Rinvoq, Upadacitinib, rheumatoid arthritis
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Xconomy
Thu, 08/15/19 - 11:39 pm
Tags:
FDA, drug approvals, AbbVie, Upadacitinib, Exondys 51, Sarepta Therapeutics, Nabriva Therapeutics, lefamulin, Roche, Rozlytrek
Allergan CEO Saunders lines up for $39M parachute after AbbVie buy
Fierce Pharma
Wed, 08/14/19 - 07:06 pm
Tags:
Allergan, executive pay, Pharma CEOs, Brent Saunders, AbbVie, M&A
Table for two: AbbVie was Allergan's only suitor in $63B takeover that shocked the industry
Fierce Pharma
Tue, 08/13/19 - 11:22 pm
Tags:
AbbVie, Allergan, M&A
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
Tue, 08/13/19 - 11:43 am
Tags:
drug approvals, FDA, AbbVie, JNJ, Novartis, Pfizer, Skyrizi, psoriasis, Vyndaqel, Zolgensma, SMA, Mayzent, multiple sclerosis, Balversa, metastatic bladder cancer
Allergan says it will shed two drugs as AbbVie takeover looms
Pharmaforum
Wed, 08/7/19 - 10:24 am
Tags:
Allergan, brazikumab, Zenprep, AbbVie, M&A
AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?
Fierce Pharma
Tue, 08/6/19 - 01:21 pm
Tags:
Allergan, AbbVie, Botox, M&A
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
Yahoo/Motley Fool
Sun, 08/4/19 - 01:02 pm
Tags:
Merck, Keytruda, AbbVie, Humira, Pfizer, Bristol-Myers Squibb, Eliquis, JNJ, Imbruvica
5 Things You Need to Know From AbbVie's Q2 Earnings Results
Motley Fool
Sat, 07/27/19 - 02:03 pm
Tags:
AbbVie, Humira, Venclexta, Imbruvica, hepatitis C, earnings
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
Fierce Pharma
Fri, 07/26/19 - 12:07 pm
Tags:
AbbVie, Humira, biosimilars, Europe, psoriasis, rheumatoid arthritis, Skyrizi
AbbVie stock up 2% after earnings beat
Marketwatch
Fri, 07/26/19 - 12:03 pm
Tags:
AbbVie, earnings

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.